Hemodynamic ABI Monitor

Launched by UNIVERSITY OF CHICAGO · Dec 5, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Hemodynamic ABI Monitor study, is looking at how heart function relates to recovery after serious brain injuries, specifically traumatic brain injury (TBI) and bleeding in the brain (intracerebral hemorrhage). The researchers want to understand how information about heart health and brain activity, which is regularly collected during treatment, can help predict patient outcomes. They will follow participants for six months after they leave the hospital to see how they are doing.

To be eligible for the study, patients need to be adults between 18 and 80 years old who were admitted to the Neurocritical Care Unit at the University of Chicago Medical Center with a severe brain injury or bleeding in the brain. They should have a low score on a scale that measures consciousness, indicating a serious condition. However, patients with pre-existing heart problems or those who show signs of severe brain damage at the time of admission cannot participate. If eligible, participants can expect to be monitored closely and have their heart and brain data recorded to help improve future treatments for similar injuries.

Gender

ALL

Eligibility criteria

• Inclusion:
• Patients who are:
• • Admitted to the University of Chicago Medical Center Neurocritical Care Unit
• • Adults between 18 years and 80
• • Admitted with Traumatic brain injury blunt and penetrating or nontraumatic intracerebral hemorrhage
• • post-resuscitation Glasgow Coma Scale (GCS) \<9
• Exclusion:
• Patients who were:
• • Pre-existing heart failure
• • Moribund or neurological exam suggesting imminent brain death (bilateral, fixed and dilated pupils) on admission
• • Major polytrauma or admitted to the surgical trauma critical care service
• • Prisoner